Labetalol hydrochloride

CLINICAL USE

Beta-adrenoceptor blocker:Hypertensive crisis, hypertension

DOSE IN NORMAL RENAL FUNCTION

Oral: 50–800 mg twice daily (in 3–4 divided doses in high doses); maximum 2.4 g daily

IV infusion

: 2 mg/minute until satisfactory response; usual total dose 50–200 mgIV bolus: 50 mg over 1 minute, repeated at 5 minute intervals to a total dose of 200 mgPregnancy: 20–160 mg/hour Hypertension after an MI: 15–120 mg/ hour

PHARMACOKINETICS

  • Molecular weight                           :364.9
  • %Protein binding                           :50
  • %Excreted unchanged in urine     : 5
  • Volume of distribution (L/kg)       :5.6
  • half-life – normal/ESRD (hrs)      :4–8/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in normal renal function
  • HD                     :Not dialysed. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Probably not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • Anaesthetics: enhanced hypotensive effect
  • Analgesics: NSAIDs antagonise hypotensive effect
  • Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone
  • Antidepressants: enhanced hypotensive effect with MAOIs; concentration of imipramine increasedAntihypertensives; enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin
  • Antimalarials: increased risk of bradycardia with mefloquineAntipsychotics enhanced hypotensive effect with phenothiazines
  • Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil
  • Diuretics: enhanced hypotensive effect
  • Moxisylyte: possible severe postural hypotension
  • Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamineTropisetron: increased risk of ventricular arrhythmias – use with caution

    ADMINISTRATION

    Reconstition

    Route

    Oral, IV

    Rate of Administration

    2 mg/minute initially then titrate according to response or to indication

    Comments

    200 mg labetalol (40 mL) to 200 mL glucose 5%Can be used undiluted. (UK Critical Care Group, Minimum Infusion Volumes for fluid restricted critically ill patients, 3rd Edition, 2006)

    OTHER INFORMATION

    No adverse effects on renal function No accumulation in renal impairment Hypoglycaemia can occur in dialysis patientsTachyphylaxis can occur with prolonged us

  • Related News